Peter Attia· MD
I'm trying to think of a single time when anything in there altered our treatment plan beyond what we already knew maybe the odd patient that shows up with a Tom 40 mutation who was otherwise in a po 33 that you think okay you're probably a little higher risk than we thought for Alzheimer's so maybe that's one exception